MedTrace Logo

Comparison of the Panax Ginseng + Associations to Ginkgo Biloba in the Treatment of Cognitive Function Disorders

NCT01637168 · Status: WITHDRAWN · Phase: PHASE3 · Type: INTERVENTIONAL

Last updated 2021-02-24

No results posted yet for this study

Summary

The purpose of this study is to evaluate the efficacy and safety of two different drugs in the treatment of patients diagnosed with memory difficulties and a decline in cognitive function.

This is a parallel distribution: a group of patients will be treated with a combination Panax Ginseng + Ginkgo Biloba + multivitamin + Polyminerals (EMS), and another group with Ginkgo Biloba (Tebonin ®).

Conditions

  • Memory Deficit

Interventions

DRUG

Panax Ginseng + Ginkgo Biloba + Polyminerals + Multivitamin

A tablet, 2 times daily (12/12 hours).

DRUG

Ginkgo Biloba (Tebonin®)

A tablet, 2 times daily (12/12 hours).

Sponsors & Collaborators

  • EMS

    lead INDUSTRY

Principal Investigators

  • Felício MD Savioli Neto · Clínica Dr. Felício Savioli

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Countries

  • Brazil

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01637168 on ClinicalTrials.gov